ALT vs LEN · rev $20.0K vs rev $34.19B
Altimmune Inc (ALT) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Altimmune Inc (ALT) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported ALT revenue for 2024-12-31 was $20.0K. Net income was -$95.1M. Revenue was down 95.3% from 2023-12-31 to 2024-12-31. ALT currently screens at market cap $527.0M.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
ALT currently screens at market cap $527.0M. LEN currently screens at market cap $0.
Not investment advice. Open the ALT and LEN stock pages for the full models.
Not investment advice.